Milk Thistle: Its Anti-Tumor Potential
Milk thistle has been used for treating liver disorders since approximately 2000 years. Silybum marianum and its seeds contain a whole family of natural compounds, called flavonolignans. Silimarin is a dry mixture of these compounds, which are extracted after processing with ethanol, methanol, and acetone. Silimarin contains mainly silibin A, silibin B, taxifolin, isosilibin A, isosilibin B, silichristin A and silidianin. Milk thistle has been suggested to inhibit cell proliferation and to induce apoptosis, while having anti-angiogenic properties, too. Its mechanisms of action involve inhibition of tumor angiogenesis biomarkers (CD31 and nestin) and molecules regulating angiogenesis (VEGF, VEGFR1, VEGFR2, phospho-Akt and HIF-1a), while other pathways such as the Wnt/β-catenin pathway, cyclin-dependent kinases and MAPK have also been implicated in its actions. Ongoing research has focused on the improvement of milk thistle’s bioavailability and its use as an adjuvant in standardized chemotherapy in the near future.
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).